Brief: TELA Bio Highlights Results from Studies on Benefits of OviTex Reinforced Tissue Matrix in Hernia Repairs
04/08/2022 12:53
Aug 4 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO INC - 24-MONTH BRAVO STUDY RESULTS SHOWED A 2.6%
RECURRENCE RATE IN DIVERSE CLINICAL SCENARIOS
* TELA BIO INC - ROBOTIC REINFORCED BIOLOGIC AUGMENTED
REPAIR
(REBAR) STUDY SHOWED A 1.9% RECURRENCE RATE AT TWO-YEAR MARK
Source text for Eikon: ID:nGNX46XJP9
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsBrief: Tela Bio - Receives FDA 510(K) Clearance For Liora Monofilament Scaffold For Soft Tissue Reinforcement
Tela Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Brief: TELA Bio Q2 Revenue USD 19.291 Million Vs. IBES Estimate USD 20 Million
Tela Bio Inc Expected To Post A Loss Of 18 Cents A Share: Earnings Preview